Mesothelioma Biomarker

Case ID: 00850

Description

Malignant mesothelioma, which is associated with asbestos or erionite exposure, is an aggressive and lethal cancer of the mesothelium, the protective lining that covers many internal organs and is most commonly found in the lungs. The inventors have discovered that misregulation of a protein called High Mobility Group Box 1 (HMGB1) is linked to mesothelioma in individuals exposed to asbestos. HMGB1 is a member of the high-mobility group protein super-family that plays important roles in biological processes like transcription, DNA repair, proliferation and inflammation. After asbestos and erionite exposure, HMGB1 is released by mesothelial cells undergoing programmed cell necrosis, initiating inflammatory processes and promoting tumor growth. The inventors have discovered HMGB1 as a highly sensitive biomarker for detection of mesothelioma and asbestos exposure.

 

Applications

Early detection of mesothelioma and asbestos exposure.

 

Advantages

  • Ability to detect mesothelioma and asbestos exposure.
  • Highly sensitive marker.

 

References

  • Jube et al., 2012. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Research, 72:3290-3301.
  • Yang et al., 2010. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA, 107:12611-12616.
Patent Information:
Inventors
Haining Yang
Michele Carbone
Harvey Pass

For information, contact:
Ann Park
Technology Licensing Associate
University of Hawaii
(808) 956-9929
apark@hawaii.edu
Keywords
Diagnostic:Marker
Healthcare:Diagnostic Tool
Healthcare:Oncology
Screening:Detection


© 2017. All Rights Reserved. Powered by Inteum